Synthesis of Novel 1,3,5‐Triazine Analogues With Selective Activity Against Pancreatic (Capan‐1) and Colorectal (HCT‐116) Carcinomas: Anticancer Potential and DNA‐Binding Affinity
Chemistry & Biodiversity · 2025-12 · 22 (12)
DOI: 10.1002/cbdv.202501362 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 30.07.2025. Verfasst von Shazia Asghar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Quaid-I-Azam University, Islamabad, Pakistan. Hauptthemen laut MEDLINE: Triazines, Antineoplastic Agents, Pancreatic Neoplasms, DNA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
A series of 2‐(2‐arylidenehydrazinyl)‐4,6‐bis(substituted‐phenoxy)‐1,3,5‐triazines (compounds 3a – o to 7a – o ) was synthesized and evaluated for DNA‐binding affinity using calf thymus DNA. Based on their DNA interaction profiles, the top three compounds from each series were selected for in vitro anticancer screening against eight human cancer cell lines, encompassing both solid tumors (glioblastoma, pancreatic adenocarcinoma, colorectal carcinoma, and lung carcinoma) and hematological malignancies (acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, and non‐Hodgkin lymphoma). Among the tested compounds, 5i and 7b demonstrated the highest anticancer potency against pancreatic adenocarcinoma (Capan‐1), with IC 50 values of 2.4 and 1.9 µM, respectively. Notably, compound 5i also exhibited strong cytotoxicity against colorectal carcinoma (HCT‐116), with an IC 50 of 2.2 µM. Additional analogues namely 3i , 3l , 6g , 6l , and 7m displayed IC 50 values ranging from 7.4 to 42.2 µM across the panel of cancer cell lines, highlighting the superior activity of 5i and 7b as promising antiproliferative agents. Molecular docking studies revealed that compound 7b formed strong interactions with the prenyl‐binding protein PDEδ, and subsequent molecular dynamics simulations confirmed the stability of the 7b –PDEδ complex, supporting its potential as a targeted anticancer agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Quaid-I-Azam University, Islamabad, Pakistan.
- Department of Chemistry, College of Education for Pure Science, University of Basrah, Basrah, Iraq.
- Department of Molecular and Medical biotechnology, College of Biotechnology, Al-Nahrain University, Baghdad, Iraq.
- Department of Chemistry, College of Science, University of Basrah, Basrah, Iraq.
ORCID-Profile: Shahid Hameed, Najim A Al-Masoudi
Zitieren
APA
Asghar, S., Aziz, A., Hameed, S., Saeed, B. A., Allami, R. H., & Al-Masoudi, N. A. (2025). Synthesis of Novel 1,3,5‐Triazine Analogues With Selective Activity Against Pancreatic (Capan‐1) and Colorectal (HCT‐116) Carcinomas: Anticancer Potential and DNA‐Binding Affinity. Chemistry & Biodiversity, 22(12). https://doi.org/10.1002/cbdv.202501362
Vancouver
Asghar S, Aziz A, Hameed S, Saeed BA, Allami RH, Al-Masoudi NA. Synthesis of Novel 1,3,5‐Triazine Analogues With Selective Activity Against Pancreatic (Capan‐1) and Colorectal (HCT‐116) Carcinomas: Anticancer Potential and DNA‐Binding Affinity. Chemistry & Biodiversity. 2025;22(12). doi:10.1002/cbdv.202501362
BibTeX
@article{Asghar2025,
author = {Asghar, Shazia and Aziz, Aftab and Hameed, Shahid and Saeed, Bahjat A and Allami, Risala H and Al-Masoudi, Najim A},
title = {Synthesis of Novel 1,3,5‐Triazine Analogues With Selective Activity Against Pancreatic (Capan‐1) and Colorectal (HCT‐116) Carcinomas: Anticancer Potential and DNA‐Binding Affinity},
journal = {Chemistry & Biodiversity},
year = {2025},
volume = {22},
number = {12},
doi = {10.1002/cbdv.202501362}
}
EUVIMED